ENTREPRENEURSHIP ARTICLES
-
![Arvin S]( "2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics")
2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM TherapeuticsArvin Soepriatna's TEEM Therapeutics is building predictive 3D human heart tissue models to improve cardiac drug screening, reduce risk earlier, and better flag cardiotoxicity.
-
![image-(5)]( "2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics")
2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia TherapeuticsStartup founders of Resilientia Tx discuss protecting cancer patients from radiation side effects, organ-on-a-chip discovery, Nucleate Boston, and early startup challenges.
-
![Chat_Jayasuriy]( "2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio")
2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBioDr. Chat Jayasuriya discusses EnkaBio’s meniscus repair therapy, fundraising, Nucleate’s impact, CEO search, and tech transfer from Brown/Rhode Island Hospital.
-
![Chris_Clifford]( "2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics")
2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic TherapeuticsChris Clifford, founder of Mimic Therapeutics, describes the company’s mission as protecting cell therapies from immune rejection, with an initial focus on Type 1 diabetes.
-
![Carlos_Ezio]( "2026 Nucleate Boston Activator Cohort Interview: Carlos Ezio — Criocore")
2026 Nucleate Boston Activator Cohort Interview: Carlos Ezio — CriocoreCarlos Ezio, co-founder and CEO of Criocore, a Harvard Medical School spinout developing bioprinted and frozen human tissue models for preclinical development.
-
![Anna Kazatskaya]( "2026 Nucleate Boston Activator Cohort Interview: Anna Kazatskaya — Fervid Therapeutics, previously Antozero")
2026 Nucleate Boston Activator Cohort Interview: Anna Kazatskaya — Fervid Therapeutics, previously AntozeroAnna Kazatskaya, CEO of Fervid Therapeutics is developing a novel peptide to treat pediatric epilepsy by increasing inhibitory synapses, backed by mouse data and a planned $2M pre-seed raise.
-
![DiscoveryDialogues_Graphic_Winston Haynes (1)]( "Discovery Dialogues: Winston Haynes, VP, Computational Sciences and Engineering, LabGenius Tx")
Discovery Dialogues: Winston Haynes, VP, Computational Sciences and Engineering, LabGenius TxDDO interviewed Winston Haynes, VP, computational sciences and engineering, LabGenius Tx, on their T-cell engagers platform, including its lead candidate LGTX-101, a Nectin-4 CD3 molecule showing strong preclinical efficacy.
-
![GettyImages-2220518026]( "Fostering Entrepreneurial Mentorship And Education: A Peek Into Nucleate Boston Activator 2026 Cohort")
Fostering Entrepreneurial Mentorship And Education: A Peek Into Nucleate Boston Activator 2026 CohortNucleate Boston’s 2026 Activator shows how mentorship, structure, and community can help promising young scientists become credible biotech founders.
-
![collaboration, teamwork, strength unity diversity-GettyImages-2180288768]( "Unfolding Protein & Antibody Discovery At PEGS 2026")
Unfolding Protein & Antibody Discovery At PEGS 2026Our editorial team covers the 2026 Protein & Antibody Engineering Summit (PEGS) in Boston -- A working map of where biologics R&D is headed.
-
![Telemedicine, human Uterus recovery-GettyImages-1397378174]( "The Next Frontier In Women's Cancer Care: Combining Cell Therapy With Immuno-Oncology")
The Next Frontier In Women's Cancer Care: Combining Cell Therapy With Immuno-OncologyThe convergence of engineered cell therapies and immuno-oncology represents a significant step forward in the quest to improve outcomes for ovarian cancer patients.
ENTREPRENEURSHIP VIDEOS
Panelists emphasized that CROs and CDMOs will be essential to scaling organ on chip adoption, but only if they commit to standardized, commercial execution rather than treating these systems as experimental add ons. As Don Ingber put it plainly, CROs “need to start buying these commercial systems and start scaling” them to make organ on chip studies operationally viable for industry.
Rahul Kakkar explains his transition from architecture student to MD and how he maintains a cardiology practice while leading Tome Biosciences, which he co-founded.